Adrenalectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Adrenalectomy is the surgical removal of one or both adrenal glands, small hormone-producing organs located on top of each kidney. The adrenal glands produce essential hormones including cortisol, aldosterone, adrenaline, and small quantities of sex hormones. Surgery becomes necessary when tumors, hyperplasia, or other pathologies cause these glands to malfunction, leading to serious hormonal imbalances that cannot be managed medically.

Adrenal tumors are relatively common, with incidental adrenal masses (incidentalomas) found in approximately 4-5% of abdominal CT scans. However, only a fraction of these require surgical removal. Functioning adrenal tumors, which produce excess hormones, and tumors with characteristics suspicious for malignancy are the primary indications for adrenalectomy. Adrenal cortical carcinoma, though rare (affecting 1-2 per million people annually), requires prompt surgical intervention.

The surgical approach has evolved significantly over the past three decades. Since the introduction of laparoscopic adrenalectomy in 1992, minimally invasive techniques have become the gold standard for most adrenal pathologies. The procedure is performed by endocrine surgeons or general surgeons with specialized training, and the choice between laparoscopic, robotic-assisted, or open approaches depends on tumor size, location, and suspected pathology.

Adrenalectomy is indicated for a range of adrenal gland disorders, both benign and malignant. The decision to operate depends on tumor functionality, size, imaging characteristics, and clinical presentation.

• Pheochromocytoma: A catecholamine-secreting tumor causing severe hypertension, palpitations, headaches, and sweating. Surgical removal is the definitive treatment.
• Cushing syndrome (adrenal origin): Cortisol-producing adenomas or hyperplasia causing weight gain, hypertension, diabetes, and osteoporosis.
• Primary hyperaldosteronism (Conn syndrome): Aldosterone-producing adenomas causing resistant hypertension and hypokalemia.
• Adrenocortical carcinoma: Rare malignant tumors of the adrenal cortex requiring complete surgical excision, often with wide margins.
• Adrenal incidentaloma: Non-functioning tumors larger than 4 cm or those with suspicious imaging features (irregular borders, high density, rapid growth).
• Adrenal metastases: Isolated adrenal metastases from lung, kidney, or other primary cancers where surgical resection may improve survival.
• Congenital adrenal hyperplasia: Rarely, bilateral adrenalectomy may be considered in severe, medically refractory cases.

Candidates for adrenalectomy include patients with functioning adrenal tumors causing documented hormonal excess, adrenal masses larger than 4 cm with indeterminate imaging characteristics, and confirmed or suspected adrenocortical carcinoma. Patients must undergo thorough hormonal evaluation, including tests for cortisol, aldosterone, catecholamines, and androgens, before surgery is recommended.

Ideal candidates are medically optimized before surgery. Patients with pheochromocytoma require 10 to 14 days of alpha-adrenergic blockade (typically phenoxybenzamine or doxazosin) followed by beta-blockade to prevent intraoperative hypertensive crises. Those with Cushing syndrome may need perioperative stress-dose steroids because the contralateral adrenal gland is often suppressed.

Relative contraindications include severe cardiopulmonary disease that precludes general anesthesia, uncorrectable coagulopathy, and extensive intra-abdominal adhesions from prior surgery (for the laparoscopic approach). Very large tumors exceeding 10-12 cm or those with evidence of local invasion may require open surgery rather than a minimally invasive approach. Patients should have a life expectancy sufficient to benefit from surgical intervention.

Laparoscopic adrenalectomy is the gold standard for benign tumors smaller than 6 cm. The transperitoneal lateral approach is most common, using 3-4 small incisions (5-12 mm) while the patient lies on their side. The retroperitoneal approach offers direct access to the adrenal gland without entering the abdominal cavity, which is advantageous for patients with prior abdominal surgery. Operative time averages 90 to 150 minutes, with blood loss typically under 100 mL.

Robotic-assisted adrenalectomy provides enhanced three-dimensional visualization and greater instrument articulation compared to standard laparoscopy. Studies demonstrate comparable outcomes to conventional laparoscopic approaches, with potential advantages for obese patients and for procedures requiring fine dissection around vascular structures. The da Vinci surgical system is the most widely used robotic platform for this procedure.

Open adrenalectomy remains necessary for large tumors (greater than 6-10 cm), suspected adrenocortical carcinoma where en bloc resection of adjacent organs may be needed, and cases where minimally invasive approaches are not feasible. Surgical approaches include anterior transabdominal, lateral flank, and posterior (less common) incisions. The anterior approach provides the best exposure for large tumors and allows thorough lymph node sampling.

Partial adrenalectomy (cortical-sparing surgery) is increasingly performed for bilateral adrenal tumors, hereditary pheochromocytoma syndromes (MEN2, VHL), and small functioning adenomas. This technique preserves adrenal cortex to reduce the risk of adrenal insufficiency while completely excising the tumor.

Adrenalectomy offers definitive treatment for hormone-secreting tumors, with cure rates exceeding 95% for benign functioning adenomas. Patients with Cushing syndrome experience resolution of metabolic abnormalities including diabetes, hypertension, and weight gain, though full hormonal recovery may take 6 to 18 months. Pheochromocytoma resection results in blood pressure normalization in approximately 70% of patients and significant improvement in the remainder.

For primary hyperaldosteronism due to a unilateral adenoma, adrenalectomy normalizes potassium levels in nearly all patients and cures or significantly improves hypertension in 60-70% of cases. Younger patients with shorter duration of hypertension and no family history of essential hypertension have the best blood pressure outcomes.

Laparoscopic adrenalectomy provides significant benefits over the open approach, including reduced postoperative pain, shorter hospital stays (1-3 days versus 5-7 days), faster return to daily activities (1-2 weeks versus 4-6 weeks), lower wound complication rates, and improved cosmetic outcomes. Mortality rates for laparoscopic adrenalectomy at experienced centers are less than 0.5%, and overall complication rates range from 5% to 10%.

General surgical risks include bleeding, infection, injury to surrounding structures, blood clots, and adverse reactions to anesthesia. The adrenal glands are located near major blood vessels (the vena cava on the right and the aorta on the left), making vascular injury a specific concern. The right adrenal vein, which drains directly into the inferior vena cava, requires particularly careful dissection. Conversion from laparoscopic to open surgery occurs in approximately 2-5% of cases, typically due to bleeding or unclear anatomy.

Procedure-specific complications include adrenal insufficiency (especially after bilateral surgery or when the contralateral gland is suppressed), adrenal crisis if steroid replacement is insufficient, pneumothorax from high diaphragmatic dissection, and pancreatic or splenic injury during left adrenalectomy. Pheochromocytoma surgery carries additional risks of severe intraoperative hypertension or hypotension, cardiac arrhythmias, and hemodynamic instability.

Long-term risks following bilateral adrenalectomy include lifelong dependence on glucocorticoid and mineralocorticoid replacement, risk of Addisonian crisis during physiologic stress (illness, surgery, trauma), and the need for permanent medical alert identification. Nelson syndrome, characterized by pituitary corticotroph tumor expansion, can occur in patients who undergo bilateral adrenalectomy for Cushing disease and requires ongoing surveillance with pituitary MRI.

After laparoscopic adrenalectomy, patients typically spend 1 to 3 days in the hospital. Pain is managed with oral analgesics, and most patients are walking and eating within 24 hours. Surgical drains are rarely needed. Patients can resume driving within 1 week, return to desk work in 1-2 weeks, and engage in full physical activity by 4-6 weeks. Open adrenalectomy requires a longer hospital stay of 5-7 days and a recovery period of 6-8 weeks.

Hormonal monitoring is essential during recovery. Patients who underwent adrenalectomy for cortisol-producing tumors require stress-dose glucocorticoid replacement (hydrocortisone) postoperatively, as the contralateral adrenal gland may remain suppressed for months. Serial morning cortisol levels and ACTH stimulation tests guide the tapering and eventual discontinuation of steroid replacement. Patients treated for pheochromocytoma require blood pressure monitoring and catecholamine level checks at 2-4 weeks and then annually to screen for recurrence.

Follow-up typically includes a surgical visit at 1-2 weeks postoperatively, endocrine evaluation at 4-6 weeks, and then periodic monitoring depending on the underlying pathology. Patients with adrenocortical carcinoma require CT or MRI imaging every 3-6 months for the first 2 years, then every 6-12 months for at least 5 years. Genetic counseling may be recommended for patients with hereditary syndromes such as MEN2 or von Hippel-Lindau disease.

The cost of adrenalectomy varies significantly based on the surgical approach, hospital setting, geographic location, and extent of the procedure. Key cost drivers include the choice between laparoscopic, robotic-assisted, or open surgery; the need for specialized intraoperative monitoring (particularly for pheochromocytoma); length of hospital stay; and whether the procedure is unilateral or bilateral.

Robotic-assisted surgery typically carries higher instrument and setup costs compared to conventional laparoscopy, though shorter hospital stays may partially offset this difference. Preoperative workup costs, including hormonal assays, imaging (CT, MRI, MIBG scans), and specialist consultations, should be factored into the total treatment cost. Patients with pheochromocytoma may require extended preoperative medical preparation and ICU-level monitoring perioperatively, adding to overall expenses.

Insurance coverage for adrenalectomy is generally good when the procedure is medically indicated, as it is considered a necessary intervention for hormone-secreting tumors and suspected malignancies. Patients should verify coverage for the specific surgical approach planned, as some insurers may have preferences regarding robotic-assisted techniques. International patients should inquire about bundled pricing packages that include preoperative workup, surgery, anesthesia, hospital stay, and initial follow-up visits.

Medical management may be appropriate for some adrenal conditions. Medications such as ketoconazole, metyrapone, or osilodrostat can reduce cortisol production in Cushing syndrome when surgery is contraindicated. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) effectively manage primary hyperaldosteronism due to bilateral adrenal hyperplasia, where adrenalectomy is not indicated.

Active surveillance is an option for small, non-functioning adrenal incidentalomas (less than 4 cm) with benign imaging characteristics. Guidelines recommend repeat imaging at 6 to 12 months and hormonal assessment annually for up to 5 years. If the mass grows by more than 1 cm or develops functioning characteristics, surgery is reconsidered.

Ablation techniques including radiofrequency ablation (RFA) and cryoablation are emerging minimally invasive alternatives for small adrenal tumors in patients who are poor surgical candidates. These image-guided percutaneous techniques have shown promising results for functional adenomas and small metastases, though long-term data are still limited. Stereotactic body radiation therapy (SBRT) may be considered for isolated adrenal metastases when surgery is not feasible, offering local control rates of 70-90% in selected patients.